Guggenheim Reiterates Buy Rating on Bruker Corporation (BRKR)

Market Context

Bruker Corporation operates in the Healthcare sector. The stock currently trades at $59.09 with a market capitalization of $7.0B. The stock has gained 53.6% over the past 52 weeks.

Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Bruker Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Bruker Corporation

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 29, 2026	Guggenheim	Buy	N/A
Jun 24, 2026	Barclays	Overweight	N/A
Jun 08, 2026	JP Morgan	Overweight	N/A
May 07, 2026	Citigroup	Neutral	N/A
May 07, 2026	UBS	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View BRKR Stock Page